Literature DB >> 79421

Comparison of the inhibition of thrombin by three plasma protease inhibitors.

M R Downing, J W Bloom, K G Mann.   

Abstract

Human alpha-thrombin is inhibited by the circulating protease inhibitors alpha1-antitrypsin, antithrombin III, and alpha2-macroglobulin. Kinetic analyses of the inhibitor thrombin interactions were carried out utilizing either fibrinogen or the synthetic substrate Bz-Phe-Val-Arg-p-nitroanilide as substrates to determine residual thrombin activity. These studies demonstrated that the inhibition of thrombin by alpha1-antitrypsin, antithrombin III, and alpha2-macroglobulin followed second-order kinetics. The rate constants for the inhibition of thrombin by alpha1-antitrypsin, antithrombin III, and alpha2-macroglobulin are 6.51 +/- 0.38 x 10(3), 3.36 +/- 0.34 x 10(5), and 2.93 +/- 0.02 x 10(4) M-1 min-1, respectively. Comparison of the second-order rate constants and the normal plasma levels of the three inhibitors demonstrates that, under the in vitro conditions utilized, antithrombin III is five times and alpha2-macroglobulin is one-third as effective as alpha1-antitrypsin in the inhibition of thrombin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 79421     DOI: 10.1021/bi00606a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.

Authors:  M F Scully; V Ellis; N Seno; V V Kakkar
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

2.  Dynamics of Thrombin Generation and Flux from Clots during Whole Human Blood Flow over Collagen/Tissue Factor Surfaces.

Authors:  Shu Zhu; Yichen Lu; Talid Sinno; Scott L Diamond
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

3.  A fragment of antithrombin that binds both heparin and thrombin.

Authors:  L Rosenfeld; I Danishefsky
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

4.  Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.

Authors:  K T Preissner; L Zwicker; G Müller-Berghaus
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

5.  Inhibition of chymotrypsin by heparin cofactor II.

Authors:  F C Church; C M Noyes; M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 6.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

7.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Authors:  Friedrich Modde; Putri Andina Agustian; Juliane Wittig; Maximilian Ernst Dämmrich; Vinzent Forstmeier; Udo Vester; Thurid Ahlenstiel; Kerstin Froede; Ulrich Budde; Anne-Margret Wingen; Anke Schwarz; Svjetlana Lovric; Jan Thomas Kielstein; Carsten Bergmann; Nadine Bachmann; Mato Nagel; Hans Heinrich Kreipe; Verena Bröcker; Clemens Luitpold Bockmeyer; Jan Ulrich Becker
Journal:  Virchows Arch       Date:  2013-03-09       Impact factor: 4.064

9.  Antithrombin III concentrate in the treatment of fulminant hepatic failure.

Authors:  K Fujiwara; K Okita; K Akamatsu; H Abe; Y Tameda; T Sakai; N Inoue; K Kanai; N Aoki; H Oka
Journal:  Gastroenterol Jpn       Date:  1988-08

10.  Thrombin activity propagates in space during blood coagulation as an excitation wave.

Authors:  N M Dashkevich; M V Ovanesov; A N Balandina; S S Karamzin; P I Shestakov; N P Soshitova; A A Tokarev; M A Panteleev; F I Ataullakhanov
Journal:  Biophys J       Date:  2012-11-20       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.